ストックスクリーナーアプリを入手
11.87
4.77%
0.54
アフターアワーズ：
11.87
前日終値:
$11.33
開ける：
$11.26
24時間の取引高:
1.28M
Relative Volume:
2.15
時価総額：
$314.85M
収益：
-
当期純損益:
$-57.91M
株価収益率:
-8.484
EPS:
-1.3991
ネットキャッシュフロー:
$-38.14M
1週間 パフォーマンス:
+12.51%
1か月 パフォーマンス:
-0.92%
6か月 パフォーマンス:
+0.68%
1年 パフォーマンス:
+108.98%
1日の値動き範囲:
$11.26
$11.97
1週間の範囲:
$10.30
$12.30
52週間の値動き範囲:
$5.34
$18.38
Tenax Therapeutics Inc Stock (TENX) Company Profile
名前
Tenax Therapeutics Inc
セクター
電話
919-855-2100
住所
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
11.87 | 306.37M | 0 | -57.91M | -38.14M | -1.3991 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-09-08 | 開始されました | Piper Sandler | Overweight |
| 2024-10-24 | 開始されました | Leerink Partners | Outperform |
| 2024-10-14 | 開始されました | Guggenheim | Buy |
| 2024-09-30 | 開始されました | William Blair | Outperform |
| 2017-05-18 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2014-12-16 | 開始されました | MLV & Co | Buy |
| 2014-11-18 | 開始されました | WallachBeth | Buy |
すべてを表示
Tenax Therapeutics Inc (TENX) 最新ニュース
TENX Maintained by Piper Sandler -- Price Target Raised to $50 - GuruFocus
Tenax Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesForward EPS Estimate - newsline.com
Tenax Therapeutics Price Target Raised to $50.00/Share From $20.00 by Piper Sandler - Moomoo
Piper Sandler raises Tenax Therapeutics price target on trial data By Investing.com - Investing.com Canada
Tenax Therapeutics (TENX) Slips 3.25% as Stock Tests Key Support LevelsMerger Arbitrage - newsline.com
T. Rowe Price discloses 586,990 Tenax shares (NASDAQ: TENX) in amended 13G - Stock Titan
What's Driving Tenax Therapeutics' Recent Surge - Kavout
Tenax Therapeutics Announces Results of 2026 Annual Meeting - TipRanks
Tenax Therapeutics (TENX) shareholders elect full board, ratify 2026 auditor - Stock Titan
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX) - The Globe and Mail
Piper Sandler Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Piper Sandler reiterates Tenax Therapeutics stock rating ahead of trial By Investing.com - Investing.com Australia
Tenax Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionGAAP Earnings Report - newsline.com
Why (TENX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Tenax Therapeutics (TENX) Rallies 1.54% as Stock Tests Key Resistance Near $12.46Institutional Buy Signals - newsline.com
Tenax Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Clinical DevelopmentEarnings Call Q&A - Newser
Tenax Therapeutics (TENX) Faces Resistance Test After 1.86% Pullback From Recent HighsShared Trade Alerts - Newser
Millennium Group (TENX) reports 1,347,130 shared votes, 5.1% stake - Stock Titan
Tectonic Therapeutics: Currently In A Catalyst Vacuum (NASDAQ:TECX) - Seeking Alpha
Understanding Momentum Shifts in (TENX) - Stock Traders Daily
LifeSci Capital Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Maintains Target Price $27 - Moomoo
[SCHEDULE 13G/A] TENAX THERAPEUTICS, INC. Amended Passive Investment Disclosure - Stock Titan
Stonepine holds 975,200 shares in Tenax Therapeutics (NASDAQ: TENX), 3.7% stake - Stock Titan
VHCP group discloses 9.99% stake in Tenax Therapeutics (NASDAQ: TENX) - Stock Titan
Point72 group discloses 533,965 shares in Tenax Therapeutics (NASDAQ: TENX) - Stock Titan
BVF affiliates hold warrants convertible into TENX shares (NASDAQ: TENX) constrained by 9.99% blocker - Stock Titan
Perceptive Advisors (NASDAQ: TENX) reports 1.45M-share position - Stock Titan
About Us - FinancialContent
Tenax Therapeutics (TENX) Stock: Consolidating at $$11.93 — Next Move Ahead 2026-05-15Insider Buying - Newser
Dellora holds ~394,665 shares in TENX (Nasdaq: TENX) per amended 13G/A - Stock Titan
RTW Investments (TENX) reports 9.99% stake in Tenax Therapeutics - Stock Titan
Tenax Therapeutics (TENX) Q1 2026 Earnings: Why the Beat MattersRetail Earnings Report - newsline.com
Tenax Therapeutics (NASDAQ: TENX) awards CFO 10K shares and 450K options - Stock Titan
TENAX THERAPEUTICS (TENX) CFO files Form 3 showing zero Common Stock owned - Stock Titan
Phase 3 spending lifts Tenax (NASDAQ: TENX) Q1 loss but extends runway - Stock Titan
TradingKey - TradingKey
Tenax Therapeutics Announces Q1 2026 Results, Advances Phase 3 LEVEL Study for TNX-103 and Expands Leadership Team - Minichart
Tenax Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
A Look at Tenax Therapeutics (TENX) Valuation After Q1 2026: EPS - GuruFocus
Tenax Therapeutics (TENX) Shares Updates on TNX-103 Phase 3 Stud - GuruFocus
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Investing News Network
Tenax Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Tenax Therapeutics (NASDAQ:TENX) Q1 2026 Slightly Beats EPS, Gears Up for Pivotal Phase 3 Data in Q3 - ChartMill
Tenax Therapeutics (NASDAQ: TENX) boosts Phase 3 spend, extends cash runway - Stock Titan
TENAX THERAPEUTICS ($TENX) Releases Q1 2026 Earnings - Quiver Quantitative
Tenax Therapeutics: Q1 Earnings Snapshot - Barchart.com
Tenax Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Guggenheim Raises Price Target for TENX, Maintains Buy Rating | TENX Stock News - GuruFocus
Millennium-linked entities file 13G/A for Tenax Therapeutics (NASDAQ: TENX) reporting ~2% stakes - Stock Titan
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Tenax Therapeutics Inc (TENX) 財務データ
収益
当期純利益
現金流量
EPS
Tenax Therapeutics Inc (TENX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Rich Stuart | Chief Medical Officer |
Dec 08 '25 |
Buy |
10.10 |
2,500 |
25,250 |
5,000 |
| Rich Stuart | Chief Medical Officer |
Dec 04 '25 |
Buy |
9.20 |
2,500 |
22,998 |
2,500 |
| Rich Stuart | Chief Medical Officer |
Dec 03 '25 |
Buy |
9.08 |
1,500 |
13,618 |
2,766 |
| Rich Stuart | Chief Medical Officer |
Dec 02 '25 |
Buy |
9.01 |
1,000 |
9,006 |
1,266 |
| Giordano Christopher Thomas | CEO |
Nov 18 '25 |
Buy |
7.75 |
1,612 |
12,500 |
1,612 |
| Giordano Christopher Thomas | CEO |
Nov 20 '25 |
Buy |
7.59 |
538 |
4,083 |
2,605 |
| Giordano Christopher Thomas | CEO |
Nov 19 '25 |
Buy |
7.51 |
455 |
3,417 |
2,067 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.25 |
6,000 |
43,490 |
5,000 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.34 |
2,000 |
14,674 |
2,000 |
| Almenoff June Sherie | Director |
Nov 18 '25 |
Buy |
7.52 |
1,900 |
14,280 |
1,993 |
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):